NHS
UK researchers warn NHS rollout of Mounjaro could widen inequalities in obesity care
Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli
UK specialists say strict early access rules for the weight-loss drug tirzepatide (Mounjaro) risk creating a “two-tier” obesity treatment system, with people who can pay privately getting faster access than those relying on the National Health Service.
An open letter opposing NHS England's decision to pull its open-source software from public view amid AI hacking fears has garnered 682 signatures, including from author Cory Doctorow and former health secretary Matt Hancock. Critics argue the policy undermines transparency and security in taxpayer-funded code.
Imeripotiwa na AI
The National Health Service in England will provide a new cream called ruxolitinib for treating non-segmental vitiligo, targeting the immune cells that cause skin pigmentation loss. Clinical trials showed it increased pigmentation in affected areas, offering a more targeted approach than existing options. The decision follows a reassessment by the National Institute for Health and Care Excellence, making it available for those aged 12 and older when other treatments fail.